![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5G2 |
Gene summary for ATP5G2 |
![]() |
Gene information | Species | Human | Gene symbol | ATP5G2 | Gene ID | 517 |
Gene name | ATP synthase membrane subunit c locus 2 | |
Gene Alias | ATP5A | |
Cytomap | 12q13.13 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q06055 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
517 | ATP5G2 | EGC | Human | Stomach | GC | 3.67e-05 | 1.88e-01 | 0.1683 |
517 | ATP5G2 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.60e-09 | -6.46e-01 | 0.02 |
517 | ATP5G2 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 9.82e-08 | -5.69e-01 | 0.0267 |
517 | ATP5G2 | PTCwithHT_1 | Human | Thyroid | HT | 1.04e-04 | -6.72e-01 | 0.0238 |
517 | ATP5G2 | PTCwithHT_6 | Human | Thyroid | HT | 9.01e-14 | -5.94e-01 | 0.02 |
517 | ATP5G2 | PTCwithHT_8 | Human | Thyroid | HT | 2.04e-11 | -6.79e-01 | 0.0351 |
517 | ATP5G2 | PTCwithoutHT_2 | Human | Thyroid | PTC | 5.59e-07 | -5.86e-01 | 0.0419 |
517 | ATP5G2 | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.44e-04 | -6.31e-01 | 0.0381 |
517 | ATP5G2 | male-WTA | Human | Thyroid | PTC | 2.83e-29 | -1.01e+00 | 0.1037 |
517 | ATP5G2 | female-WTA | Human | Thyroid | PTC | 9.45e-16 | -1.01e+00 | 0.0726 |
517 | ATP5G2 | nodule-WTA | Human | Thyroid | goiters | 6.56e-32 | -1.01e+00 | 0.0534 |
517 | ATP5G2 | PTC01 | Human | Thyroid | PTC | 2.83e-29 | -1.01e+00 | 0.1899 |
517 | ATP5G2 | PTC03 | Human | Thyroid | PTC | 1.52e-12 | -1.01e+00 | 0.1784 |
517 | ATP5G2 | PTC04 | Human | Thyroid | PTC | 1.85e-30 | -1.01e+00 | 0.1927 |
517 | ATP5G2 | PTC05 | Human | Thyroid | PTC | 5.15e-13 | -1.01e+00 | 0.2065 |
517 | ATP5G2 | PTC06 | Human | Thyroid | PTC | 2.80e-25 | -1.01e+00 | 0.2057 |
517 | ATP5G2 | PTC07 | Human | Thyroid | PTC | 1.84e-32 | -1.01e+00 | 0.2044 |
517 | ATP5G2 | ATC08 | Human | Thyroid | ATC | 6.57e-12 | -1.01e+00 | 0.0541 |
517 | ATP5G2 | ATC09 | Human | Thyroid | ATC | 1.76e-13 | -1.01e+00 | 0.2871 |
517 | ATP5G2 | ATC11 | Human | Thyroid | ATC | 8.80e-03 | -1.01e+00 | 0.3386 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5G2 | deletion | Frame_Shift_Del | novel | c.36delN | p.Ser13ProfsTer44 | p.S13Pfs*44 | Q06055 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
ATP5G2 | SNV | Missense_Mutation | novel | c.510N>A | p.Phe170Leu | p.F170L | Q06055 | protein_coding | deleterious(0.02) | possibly_damaging(0.793) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ATP5G2 | SNV | Missense_Mutation | c.533N>T | p.Ala178Val | p.A178V | Q06055 | protein_coding | deleterious(0.04) | benign(0.19) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ATP5G2 | SNV | Missense_Mutation | rs566625928 | c.239N>A | p.Arg80His | p.R80H | Q06055 | protein_coding | deleterious_low_confidence(0.05) | benign(0.01) | TCGA-A5-A0GR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP5G2 | SNV | Missense_Mutation | rs767073937 | c.313N>C | p.Cys105Arg | p.C105R | Q06055 | protein_coding | tolerated_low_confidence(0.67) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ATP5G2 | SNV | Missense_Mutation | rs566625928 | c.239G>A | p.Arg80His | p.R80H | Q06055 | protein_coding | deleterious_low_confidence(0.05) | benign(0.01) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5G2 | SNV | Missense_Mutation | novel | c.337N>G | p.Ser113Gly | p.S113G | Q06055 | protein_coding | deleterious_low_confidence(0.04) | benign(0.084) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5G2 | SNV | Missense_Mutation | novel | c.463N>T | p.Leu155Phe | p.L155F | Q06055 | protein_coding | deleterious(0.02) | probably_damaging(0.967) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP5G2 | SNV | Missense_Mutation | novel | c.434G>T | p.Gly145Val | p.G145V | Q06055 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-73-A9RS-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
ATP5G2 | SNV | Missense_Mutation | novel | c.76N>T | p.Ala26Ser | p.A26S | Q06055 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.751) | TCGA-21-1075-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |